MiNK Therapeutics (INKT) announced the appointment of Terese Hammond, MD as Head of Inflammatory and Pulmonary Diseases, effective immediately. In her role at MiNK, Dr. Hammond will lead the company’s inflammatory and pulmonary disease portfolio, which include the imminent grant-supported clinical trial in GVHD and the planned late-stage trial in severe pulmonary disease
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
- Mink Therapeutics’ Earnings Call: Clinical Progress Amid Financial Challenges
- Target downgraded, Salesforce upgraded: Wall Street’s top analyst calls
- MiNK Therapeutics: Promising Clinical Trials and Growth Prospects Lead to Buy Rating
- MiNK Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
- MiNK Therapeutics Reports Q2 2025 Milestones and Financials